SplitMay 22, 2026, 04:16 PM
Kairos Pharma to Vote on 1:3 to 1:250 Reverse Stock Split
AI Summary
Kairos Pharma, Ltd. announced its 2026 Annual Meeting of Stockholders on June 29, 2026, where shareholders will vote on several key proposals. These include the election of four directors, the ratification of Weinberg & Company, P.A. as independent auditors, and an advisory vote on executive compensation. The most significant proposals involve approving an amendment to the Certificate of Incorporation to effect a reverse stock split with a ratio between 1:3 and 1:250, and an amendment to the 2023 Equity Incentive Plan to increase available shares by 5,000,000 and add an evergreen provision.
Key Highlights
- Annual Meeting of Stockholders scheduled for June 29, 2026, to be held virtually.
- Proposal to elect four directors to the Board.
- Proposal to ratify Weinberg & Company, P.A. as independent registered public accounting firm for 2026.
- Proposal to approve an amendment for a reverse stock split with a ratio between 1:3 and 1:250.
- Advisory vote on the Company's executive compensation.
- Proposal to amend the 2023 Equity Incentive Plan to add 5,000,000 shares.
- The 2023 Equity Incentive Plan amendment also includes an evergreen provision for a 5% annual increase for 10 years.
- Stockholders of record as of May 15, 2026, are entitled to vote, with 21,411,198 shares outstanding.
Price Impact
More from KAPA